BLOOD PLASMA DERIVATIVES MARKET ANALYSIS

Blood Plasma Derivatives MarketSize and Trends

Figure 1. Global Blood Plasma Derivatives Market Share (%), by Region, 2023

Global Blood Plasma Derivatives Market: Segmentation:

The global blood plasma derivatives market report is segmented into Type, Application, and Region.

Based on Type, the market is segmented into Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others. Out of which, Albumin Segment is expected to dominate the blood plasma derivatives market over the forecast period and this is attributed to the increase in albumin product usage for non-therapeutic application and rise in adoption of albumin products.

Immunoglobulin Segment is also expected to witness significant growth in the near future and this is owing to the growing use of immunoglobulins in various therapeutic areas.

Based on Application, the market is segmented into Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand's disease (VWD), and Other Application. Out of which, Hemophilia Segment is expected to dominate the market over the forecast period and this is attributed to the rise in burden of Hemophilia.

Immunodeficiency Diseases Segment is also expected to witness significant growth in the near future and this is owing to increasing prevalence of immune deficiency disorders.

Figure 2. Global Blood Plasma Derivatives Market Share (%), by Type, 2023

Global Blood Plasma Derivatives Market Trends:

High demand for immunoglobulin is a recent trend

Intravenous immunoglobulin (IVIG) is a pooled antibody, and a biological agent used to manage various immunodeficiency states and a plethora of other conditions. The ultimate goal of therapy is to normalize a compromised immune system. According to the study published in May 2022 in the Therapeutics advances in Chronic Diseases, intravenous immunoglobulin (IVIG) was reported to be one of the top three most used monotherapy in livedoid vasculopathy (LV). Moreover, it is a safe and effective treatment for rare diseases. The trend of using immunoglobulins (Ig) in various therapeutic areas is expected to continue over the forecast period.

Introduction of novel products is another trend

Players in the market players are engaged in various activities, such as product development and launches, partnerships, mergers, and acquisitions to bring technologically advanced products and techniques in the market. For instance, in January 2022, Octapharma announced that the indication for cutaquig, a human immunoglobulin for subcutaneous administration, has been expanded in the European Union (EU), providing more flexible treatment options to a wider range of patients with acquired immune deficiencies. This trend is also expected to continue over the forecast period.